Erlotinib hydrochloride. Oncolytic EGF receptor inhibitor

Drugs of the Future

Volumn 27, Issue 10, 2002, Pages 923-934

  Sorbera, L A ^a   Castaner J ^a   Silvestre, J S ^a   Bayes M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CANERTINIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; GENISTEIN; LAPATINIB; NEU DIFFERENTIATION FACTOR; PACLITAXEL; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ACNE; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER GRADING; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; EPIDERMIS HYPERPLASIA; FATIGUE; FEBRILE NEUTROPENIA; GENE OVEREXPRESSION; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROTEIN PHOSPHORYLATION; RASH; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; SOLID TUMOR; STEADY STATE; STOMACH EMPTYING; VOMITING;

EID: 0036821064     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.10.697002     Document Type: Review

References (77)

1. Schnur, R.C., Arnold, L.D. (Pfizer Inc.). Quinazoline derivs. EP 0817775, EP 1110953, JP 1998506633, WO 9630347.
2. Schnur, R.C., Arnold, L.D. (Pfizer Inc.). Alkynyl and azido-sub-std. 4-anilinoquinazolines. US 5747498.
3. Lehner, R.S., Norris, T., Santafianos, D.P. (Pfizer Products Inc.). Processes and intermediates for preparing anti-cancer compounds. EP 1044969, JP 2000290262.
4. Blume-Jensen, P., Hunter, T. Oncogenic kinase signalling. Nature 2001, 411: 355-65.
5. Ullrich, A., Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61: 203-12.
6. Carpenter, G., Cohen, S. Epidermal growth factor. J Biol Chem 1990, 265: 7709-12.
7. Wikstrand, C.J., Bigner, D.D. Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-α. J Natl Cancer Inst 1998, 90: 799-801.
8. Aaronson, S.A. Growth factors and cancer Science 1991, 254: 1146-53.
9. Wells, A. EGF receptor. Int J Biochem Cell Biol 1999, 31: 637-43.
10. Woodburn. J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999, 82: 241-50.
11. Schreiber, A.B., Winkler, M.E., Derynck, R. Transforming growth factor-α: A more potent angiogenic mediator than epidermal growth factor. Science 1986, 232: 1250-3.
12. Salomon, D.S., Brandt, R., Ciardiello, F., Normanno, N. Epidermal growth factor related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19: 183-232.
13. Ramp, U., Jaquet, K., Reinecke, P., Schardt, C., Friebe, U., Nitsch, T., Marx, N., Gabbert, H.E., Gerharz, C.D. Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type. J Urol 1997, 157: 2345-50.
14. Naef, M., Yokoyama, M., Friess, H., Buchler, M.W., Korc, M. Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma. Int J Cancer 1996, 66: 315-21.
15. Inui, Y., Higashiyama, S., Kawata, S., Tamura, S., Miyagawa, J., Taniguchi, N., Matsuzawa, Y. Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma. Gastroenterology 1994, 107: 1799-804.
16. Levitzki, A., Gazit, A. Tyrosine kinase inhibition: An approach to drug development. Science 1995, 267: 1782-8.
17. Traxler, P., Furet, P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Ther 1999, 82: 195-206.
18. Moyer, J.D., Barbacci, E.G., Iwata, K.K. et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997, 57: 4838-48.
19. Halatsch, M.-E., Gehrke, E.E., Schmidt, U., Kolenda, H. Antiproliferative effect of CP 358,774, an inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, on glioblastoma multiforme (GBM) cells in vitro. Proc Am Assoc Cancer Res 2001, 42: Abst 4578.
20. Pollack, V.A., Savage, D.M., Baker, D.A. et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP 358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999, 291: 739-48.
21. Iwata, K.K., Provoncha, K., Gibson, N. Inhibition of mutant EGFRv1II transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva). Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 79.
22. Ling, Y.-H., Donato, N.J., Perez-Soler, R. Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines. Cancer Chemother Pharmacol 2001, 47: 473-80.
23. Akita, R.W., Dugger, D., Phillips, G.D.L., Lafleur, M., Kang, K., Erickson, S., Romero, M., Schwall, R.H., Sliwkowski, M.X. Effects of the EGFR inhibitor Tarceva™ on activated ErbB2. Proc Am Assoc Cancer Res 2002, 43: Abst 4973.
24. Totpal, K., Phillips, G.D.L., Balter, I., Sliwkowski, M.X. Augmentation of rhMAb2C4 induced growth inhibition by Tarceva™ the EGFR tyrosine kinase inhibitor on human breast cancer cell line. Proc Am Assoc Cancer Res 2002, 43: Abst 3889.
25. De Bono, J.S., Rowinsky, E., Takimoto, C., Piazza, G., Medina, L. Antitumor in vitro activity of an inhibitor of EGFR tyorsine kinase against colony formation of freshly explanted human tumor cells in the human tumor cloning assay. Proc Am Assoc Cancer Res 2002, 43: Abst 3895.
26. Updyke, L., Smolarek, T., Guzzie, P. et al. Pre-clinical safety assessment of CP-358,774, an epidermal growth factor receptor tyrosine kinase inhibitor Proc Am Assoc Cancer Res 1997, 38: Abst 3140.
27. Smolarek, T., Vaidya, M.P., Davis, J. et al. Pharmacokinetics and metabolism of CP-358,774, a potent and selective EGF receptor tyrosine kinase inhibitor. Proc Am Assoc Cancer Res 1997, 38: Abst 4010.
28. Potchoiba, M.J., West, M., Smolarek, T.A., Pollack, V., Baker, D. Tissue distribution of CP-358,774, a selective and potent EGF receptor tyrosine kinase inhibitor in HN5 tumor-bearing, athymic nu/nu (nude) mice. Proc Am Assoc Cancer Res 1997, 38: Abst 3139.
29. Siu, L.L., Hidalgo, M., Nemunaitis, J. et al. Dose and schedule-duration escalation of the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774: A phase I and pharmacokinetic (PK) study. Proc Am Soc Clin Oncol 1999, 18: Abst 1498.
30. Karp, D.D., Silberman, S.L., Csudae, R. et al. Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 1999, 18: Abst 1499.
31. Hidalgo, M., Siu, L.L., Nemunaitis, J. et al. Phase landpharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19: 3267-79.
32. Hidalgo, M., Malik, S., Rowinsky, E., Miller, A., Duffey, D., de'Grafenried, L., Siu, L., Simmons, C., Kreisberg, J., Brattain, M. Inhibition of the epidermal growth factor receptor (EGFR) by OSI-774, a specific EGFR inhibitor in malignant and normal tissues of cancer patients., Proc Am Soc Clin Oncol 2001, 20(Part 1): Abst 281.
33. Malik, S., Brattain, M., Rowinsky, E. et al. Inhibition of the epidermal growth factor receptor (EGFR) activation and signaling by OSI-774, a novel EGFR inhibitor, in clinical specimens and neck carcinoma. Proc Am Assoc Cancer Res 2001, 42: Abst 4565.
34. Rowinsky, E.K., Hammond, L., Siu, L. et al. Dose-schedule-finding, pharmacokinetic (PK), biologic, and functional imaging studies of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor. Proc Am Soc Clin Oncol 2001, 20(Part 1): Abst 5.
35. 18FDG-PET evaluation of patients treated with the epidermal growth factor (EGFR) tyrosine (TK) inhibitor CP-358,774. Clin Cancer Res 2000, 6(Suppl.): Abst 385.
36. Rogers, L.R., Kaelin, W., Nadler, P., Shields, A.F., LoRusso, P. Response of cerebellar hemangioblastomas associated with von Hippel-Lindau disease to OSI-774 (Tarceva™). Proc Am Soc Clin Oncol 2002, 21 (Part 2): Abst 2111.
37. Forouzesh, B., Hidalgo, M., Takimoto, C. et al. Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 in combination with docetaxel. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 81.
38. Forero, L., Patnaik, A., Hammond, L.A. et al. Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin. Proc Am Soc Clin Oncol 2002, 21 (Part 2): Abst 1908.
39. Senzer, N.N., Soulieres, D., Siu, L. et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 2001, 20(Part 1): Abst 6.
40. Perez-Soler, R., Chachoua, A., Huberman, M. et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001, 20(Part 1): Abst 1235.
41. Finkler, N., Gordon, A., Crozier, M. et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc Am Soc Clin Oncol 2001, 20(Part 1): Abst 831.
42. Two international studies of OSI-774 commence in NSCLC and pancreatic cancer DailyDrugNews.com (Daily Essentials) October 24, 2001.
43. Initial stage completed in phase III trial of Tarceva in pancreatic cancer. DailyDrugNews.com (Daily Essentials) May 3, 2002.
44. OSI-774 to be tested in combination therapy for NSCLC. DailyDrugNews.com (Daily Essentials) July 26, 2001.
45. Phase III Tarceva trial in NSCLC completes enrollment. DailyDrugNews.com (Daily Essentials) September 18, 2002.
46. Tarceva enters new phase III trial in combination with gemcitabine and cisplatin. DailyDrugNews.com (Daily Essentials) November 23, 2001.
47. Fast track designation for Tarceva in chemotherapy-naive NSCLC. DailyDrugNews.com (Daily Essentials) May 15, 2002.
48. Tarceva receives second fast track designation. DailyDrugNews.com (September 25, 2002).
49. Smaill, J.B., Rewcastle, G.W., Loo, J.A. et al. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med Chem 2000, 43: 1380-97.
50. Denny, W.A. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases. Farmaco 2001, 56: 51-6.
51. Gieseg, M.A., de Bock, C., Ferguson, L.R., Denny, W.A. Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033. Anti-Cancer Drugs 2001, 12: 683-90.
52. Bruns, C.J., Solorzano, C.C., Harbison, M.T. et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000, 60: 2926-35.
53. Greenberger, L.M., Discafani, C., Wang, Y.-F., Tsou, H.-R., Overbek, E.G., Nilakantan, R., Frost, P., Wissner, A. EKB-569: A new irreversible inhibitor of epidermal growth factor receptor tyrosine kinase for the treatment of cancer. Clin Cancer Res 2000, 6(Suppl.): Abst 388.
54. Rusnak, D.W., Affleck, K., Cockerill, S.G. et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer. Cancer Res 2001, 61: 7196-203.
55. Christensen, J.G., Schreck, R.E., Chan, E. et al. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res 2001, 7: 4230-8.
56. Budillon, A., Di Gennaro, E., Bruzzese, F., Errico, S., Caraglia, M., Avallone, A., Pirozzi, G., Cornelia, G., Caponigro, F. Synergestic antitumour activity of IFNalpha in combination with ZD 1839 (Iressa™), and EGFR tyrosine inhibitor, in HNSCC and melanoma cell lines. Clin Cancer Res 2000, 6(Suppl.): Abst 378.
57. Raben, D., Helfrich, B., Phistry, M., Chan, D., Bunn, P. Jr. ZD1839 ("Iressa") and EGFR-TKI, potentiates radiation/chemotherapy cytotoxicity in human non-small cell lung cancer (NSCLC) lines. Clin Cancer Res 2000, 6(Suppl.): Abst LB4.
58. Geissler, J.F., Roesel, J.L., Meyer, T., Trinks, U.P., Traxler, P., Lydon, N.B. Benzopyranones and benzothiopyranones: A class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase. Cancer Res 1992, 52: 4492-8.
59. Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M., Fukami, Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987, 262: 5592-5.
60. Li, W., Weber, G. Synergistic action of tiazofurin and genistein in human ovarian carcinoma cells. Proc Am Assoc Cancer Res 1998, 39: Abst 2166.
61. 2/M cell cycle arrest and cyclin B1 accumulation in MCF-7 breast cancer cells: A possible mechanism for the preventive action of genistein. Proc Am Assoc Cancer Res 1998, 39: Abst 2648.
62. Akama, T., Shida, Y., Sugaya, T., Ishida, H., Gomi, K., Kasai, M. Novel 5-aminoflavone derivatives as specific antitumor agents in breast cancer. J Med Chem 1996, 39: 3461-9.
63. Lee, K.T., Sohn, I.C., Kim, Y.K., Choi, J.H., Choi, J.W., Park, H.J., Itoh, Y., Miyamoto, K. Tectorigenin, an isoflavone of Pueraria thunbergiana Benth., induces differentiation and apoptosis in human promyelocytic leukemia HL-60 cells. Biol Pharm Bull 2001, 24: 1117-21.
64. Shen, F., Weber, G. Quercetin and genistein reduced signal transduction activity and provided synergistic cytotoxicity in human ovarian carcinoma cells. Proc Am Assoc Cancer Res 1998, 39: 3795.
65. Stevens, M.F., McCall, C.J., Lelieveld, P., Alexander, P., Richter, A., Davies, D.E. Structural studies on bioactive compounds. 23. Synthesis of polyhydroxylated 2-phenylbenzothiazoles and a comparison of their cytotoxicities and pharmacological properties with genistein and quercetin. J Med Chem 1994, 37: 1689-95.
66. Keith, B.R., Allen, P.P., Alligood, K.J., Crosby, R.M., Lackey, K., Gilmer, T.M., Mullin, R.J. Anti-tumor activity of GW2016 in the ErbB-2 positive human breast cancer xenograft, BT474. Proc Am Assoc Cancer Res 2001, 42: Abst 4308.
67. Mullin, R.J., Alligood, K.J., Allen, P.P., Crosby, R.M., Keith, B.R., Lackey, K., Gilmer, T.M., Griffin, R.J., Murray, D.M., Tadepalli, S.M. Antitumor activity of GW2016 in the EGFR positive human head and neck cancer xenograft, HN5. Proc Am Assoc Cancer Res 2001, 42: 4579.
68. Barbacci, E.G., Cunningham, A., Iwata, K., Moyer, J.D., Miller, P.E. Induction of cell cycle arrest by inhibitors of epidermal growth factor receptor (EGFR) kinase activity. Proc Am Assoc Cancer Res 1997, 38: Abst 3143.
69. Iwata, K., Miller, P.E., Barbacci, E.G. et al. CP-358,774: A selective EGFR kinase inhibitor with potent antiproliferative activity against HN5 head and neck tumor cells. Proc Am Assoc Cancer Res 1997, 38: Abst 4248.
70. Pollack, V.A., Savage, D.M., Baker, D.A. et al. Therapy of human carcinomas in athymic mice by inhibition of EGF receptor-mediated signal transduction with CP-358774: Dynamics of receptor inhibition and anti-tumor effects. Proc Am Assoc Cancer Res 1997, 38: Abst 4249.
71. Miller, P.E., Robinson, J., Moyer, J.D., Pustilnik, L.R., Baker, D., Barbacci, E.G. CP-358,774, a selective EGFR kinase inhibitor, inhibits phosphorylation of SHC and retinoblastoma protein in human tumor xenografts. Proc Am Assoc Cancer Res 1998, 39: Abst 3808.
72. Allen, L.F., Cerna, C., Gomez, L., Yochmowitz, M., Medina, L., Weitman, S. Investigation of the effects of CP-358,774 on various human tumor specimens taken directly from patients. Clin Cancer Res 2000, 6(Suppl.): Abst 384.
73. Bonomi, P., Perez-Soler, R., Chachoua, A. et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), CP-358,774, following platinum-based chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). Clin Cancer Res 2000, 6(Suppl.): Abst 386.
74. Siu, L.L., Soulieres, D., Senzer, N., Agarwala, S., Vokes, E., Fisher, D., Marsolais, C., Ferrante, K.J., Allen, L.F. A phase II, multi-center study of the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI), CP-358,774 in patients (pts) with advanced squamous cell carcinoma of the head and neck. Clin Cancer Res 2000, 6(Suppl.): Abst 387.
75. Haley, J.D., Thelemann, A., Pan, H., Fenyo, D., Iwata, K., Bruskin, A. Probing EGFR signalling in NH5 squamous carcinoma using the quinazoline EGFR inhibitor OSI-774 and coupled affinity chromatography and mass spectrometry. Proc Am Assoc Cancer Res 2001, 42: Abst 5140.
76. Iwata, K.K., Provoncha, K., Haley, J.D., Bruskin, A. Effect of OSI-774 on EGFR and EGFRvIII receptor dimerization. Proc Am Assoc Cancer Res 2002, 43: Abst 1006.
77. Baselga, J. EGF receptor as a target: Preclinical and clinical studies. Proc Am Assoc Cancer Res 2002, 43: Invited Abstracts.